The antiphospholipid antibodies included as laboratory criteria of the antiphospholipid syndrome (APS) are antibodies reacting with anionic phospholipids – anticardiolipin antibodies and lupus anticoagulant – and with β2-glycoprotein I. However, antibodies reacting with phosphatidylethanolamine (aPE), a zwitterionic phospholipid, have also been described to be associated with the main features of APS. The objectives of this review are to describe the characteristics of aPE and to bring attention to recent evidence that aPE are correlated with the main clinical features of APS, notably, in the absence of the laboratory criteria of this syndrome.
1 McIntyre JA Wagenknecht DR . Anti-phosphatidylethanolamine (aPE) antibodies: a survey. J Autoimmun2000; 15: 185–193.
2.
2 Smirnov MD Ford DA Esmon CT Esmon NL . The effect of membrane composition on the hemostatic balance. Biochemistry1999; 38: 3591–3598.
3.
3 Norstrøm EA Steen M Tran S Dahlbäck B . Importance of protein S and phospholipid for activated protein C-mediated cleavages in factor Va. J Biol Chem2003; 278: 24904–24911.
4.
4 Baumgärtner P Geiger M Zieseniss S . Phosphatidylethanolamine critically supports internalization of cell-penetrating protein C inhibitor. J Cell Biol2007; 179: 793–804.
5.
5 Tsuda T Yoshimura H Hamasaki N . Effect of phosphatidylcholine, phosphatidylethanolamine and lysophosphatidylcholine on the activated factor X-prothrombin system. Blood Coagul Fibrinolysis2006; 17: 465–469.
6.
6 Rauch J Tannenbaum M Tannenbaum H . Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J Biol Chem1986; 261: 9672–9677.
7.
7 Janoff AS Rauch J . The structural specificity of anti-phospholipid antibodies in autoimmune disease. Chem Phys Lipids1986; 40: 315–332.
8.
8 Rauch J Tannenbaum M Neville C Fortin PR . Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin. Thromb Haemost1998; 80: 936–941.
9.
9 Drouvalakis KA Buchanan RR . Phospholipid specificity of autoimmune and drug induced lupus anticoagulants; association of phosphatidylethanolamine reactivity with thrombosis in autoimmune disease. J Rheumatol1998; 25: 290–295.
10.
10 Drouvalakis KA Neeson PJ Buchanan RR . Detection of anti-phosphatidylethanolamine antibodies using flow cytometry. Cytometry1999; 36: 46–51.
11.
11 Berard M Boffa MC . Influence of the phosphatidylethanolamine (PE) and bovine serum origins on anti-PE antibody detection by ELISA. Thromb Res1997; 85: 439–442.
12.
12 Drouvalakis KA Buchanan RR . Microtitre plate and assay buffer alter detection of antiphosphatidylethanolamine antibodies in lupus anticoagulant positive plasma. Thromb Res1999; 94: 205–212.
13.
13 Sugi T McIntyre JA . Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood1995; 86: 3083–3089.
14.
14 Sugi T McIntyre JA . Certain autoantibodies to phosphatidylethanolamine (aPE) recognize factor XI and prekallikrein independently or in addition to the kininogens. J Autoimmun2001; 17: 207–214.
15.
15 Vlachoyiannopoulos PG Beigbeder G Dueymes M . Antibodies to phosphatidylethanolamine in antiphospholipid syndrome and systemic lupus erythematosus: their correlation with anticardiolipin antibodies and beta 2 glycoprotein-I plasma levels. Autoimmunity1993; 16: 245–249.
16.
16 Sanmarco M Alessi MC Harle JR . Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb Haemost2001; 85: 800–805.
17.
17 Staub HL Harris EN Khamashta MA Savidge G Chahade WH Hughes GR . Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. Ann Rheum Dis1989; 48: 166–169.
18.
18 Berard M Chantome R Marcelli A Boffa MC . Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases. J Rheumatol1996; 23: 1369–1374.
19.
19 Sanmarco M Gayet S Alessi MC . Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost2007; 97: 949–954.
20.
20 Sugi T Katsunuma J Izumi SI McIntyre JA Makino T . Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses. Fertil Steril1999; 71: 1060–1065.
21.
21 Gris JC Quéré I Sanmarco M . Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early fœtal loss. Thromb Haemost2000; 84: 228–236.
22.
22 Sugi T Matsubayashi H Inomo A Dan L Makino TJ . Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss. Obstet Gynaecol Res2004; 30: 326–332.
23.
23 Sanmarco M Bardin N Camoin L . Antigenic profile, prevalence, and clinical significance of antiphospholipid antibodies in women referred for in vitro fertilization. Ann N Y Acad Sci2007; 1108: 457–465.
24.
24 Hughes GRV Khamashta MA . Sero-negative antiphospholipid syndrome. Ann Rheum Dis2003; 62: 1127.
